Remove Drug Development Remove Drug Pricing Remove Pharmaceutical Manufacturing
article thumbnail

STAT+: Pharmalittle: Mid-year price hikes for U.S. drugs reaches new heights; onetime biotech CEO Vivek Ramaswamy sparks debate at GOP debate

STAT

  A new analysis of mid-year price hikes has found that, despite policy changes under the Inflation Reduction Act, drug prices are on the rise , STAT reports. Biden health officials are expected to reveal the initial list before the stock market opens Tuesday morning.

article thumbnail

How could tariffs impact the pharmaceutical industry?

European Pharmaceutical Review

Impact on drug pricing and affordability Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation” Rising production costs due to tariffs could lead to higher drug prices, particularly in markets where pricing pressures are already a concern.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

January 2025 Newsletter

Safe Biologics

This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. What Will 2025 Mean for Medicare Drug Price Setting Under the IRA?

article thumbnail

Divided Congress paves way for drug price reforms on Biden’s watch

pharmaphorum

High drug prices was a touchstone issue in the 2016 elections and Biden has also made this a priority in his campaigning. This includes reducing drug costs to consumers in the United States. “If any of these are successful, it could materially impact profit margins for the drug manufacturers.”